ALBI Grade Determines Post‐progression Survivals after Sorafenib Treatment Failure in Advanced HCC Patients: A Model for Second‐Line Trial Selection: 790. (October 2016) - Lin, Han‐Chieh; Lee, Pei‐Chang; Huang, Yi‐Hsiang; Su, Chien‐Wei; Hou, Ming‐Chih